Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10

BACKGROUND: The human epidermal growth factor receptor (EGFR) is an important therapeutic target in oncology, and three different types of EGFR inhibitors have been approved for the treatment of cancer patients. However, there has been no clear association between the expression levels of EGFR prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Modjtahedi, H, Khelwatty, S A, Kirk, R S, Seddon, A M, Essapen, S, Del Vecchio, C A, Wong, A J, Eccles, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305949/
https://www.ncbi.nlm.nih.gov/pubmed/22315050
http://dx.doi.org/10.1038/bjc.2012.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305949/
https://www.ncbi.nlm.nih.gov/pubmed/22315050
http://dx.doi.org/10.1038/bjc.2012.27

Ejemplares similares